Three months of ipamorelin treatment counteracted methylprednisolone-induced decreases in bone formation and bone mineral content in adult rats, demonstrating sustained bone-protective effects against steroid damage.
3-month protectionIpamorelin maintained bone formation and mineral content through 3 months of concurrent steroid treatment in adult rats
What the researchers found
Three months of ipamorelin (SC injection) counteracted methylprednisolone-induced decreases in bone formation rate, bone mineral content, and partially preserved skeletal muscle mass in adult female rats.
Why it matters
Steroid-induced osteoporosis affects millions of patients on chronic corticosteroids. A GH secretagogue that maintains bone formation during steroid therapy could prevent fractures and disability.
How the study worked
Animal study in 8-month-old female rats. Groups treated for 3 months with: vehicle, methylprednisolone alone, ipamorelin alone, or methylprednisolone + ipamorelin. Bone formation rate, bone mineral content, and muscle mass measured.
What this study cannot tell us
Rat study. Three months in rats is relatively long but may not predict lifetime steroid use effects in humans. Adult female rats used; effects may differ by sex and age.
How to read the evidence
Preliminary but clinically relevant animal evidence with long treatment duration and multiple bone outcome measures.
When this study was published
Published in 2001. Ipamorelin's bone-protective effects during steroid therapy remain relevant for clinical development.
The bigger picture
The clinical need for bone protection during steroid therapy is enormous — from autoimmune diseases to transplant medicine to chronic lung disease. Ipamorelin's bone-sparing effect in this context is clinically highly relevant.
Questions still open
- Would ipamorelin prevent steroid-induced fractures in human patients?
- Does the bone protective effect persist after ipamorelin discontinuation?
- Can ipamorelin be used with any steroid, or is the protection steroid-specific?
Common questions
Can ipamorelin prevent steroid-induced bone loss?
Why is this important for patients on steroids?
Read the original research
The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats.
Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 11(5), 266-72
Citation
Andersen, N B; Malmlöf, K; Johansen, P B; Andreassen, T T; Ørtoft, G; Oxlund, H. (2001). The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats.. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 11(5), 266-72.